TransUnion 8-K, filed Oct 26, 2021
TransUnion (TRU)
8-K
2021-10-26
For: 2021-10-26
View Original
Added on
April 07, 2026
About this 8-K
TransUnion filed this 8-K on October 26, 2021.
Items reported
- Item 1.01: Entered into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date Earliest Event Reported): October 26, 2021
____________________
(Exact name of registrant as specified in its charter)
____________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (312 ) 985-2000
____________________
Check the appropriate box below if the Form 8−K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
Stock Purchase Agreement
On October 26, 2021, Trans Union LLC (the “Company”), a Delaware limited liability company and subsidiary of TransUnion, a Delaware corporation, entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with nThrive, Inc. (the “Purchaser”), a Delaware corporation backed by Clearlake Capital Group L.P. (the “Sponsor”) and its affiliated funds, pursuant to which, among other matters, the Company has agreed to sell its healthcare revenue cycle management and data analytics insights business (referred to herein as the “Business”) to the Purchaser for an aggregate purchase price of $1.735 billion, subject to customary adjustments as set forth in the Stock Purchase Agreement relating to working capital, cash, indebtedness and transaction expenses of the Business (the “Transaction”).
The Stock Purchase Agreement provides that the closing of the Transaction is subject to the satisfaction or waiver of customary closing conditions, including, among other things, (i) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and (ii) the absence of any law or governmental order enjoining, making illegal or otherwise prohibiting the consummation of the Transaction. The Company is targeting a closing of the Transaction in the fourth quarter of 2021, subject to the satisfaction or waiver of such customary closing conditions.
The Stock Purchase Agreement contains customary representations, warranties and covenants from the Company and the Purchaser. Between the date of the Stock Purchase Agreement and the closing of the Transaction, subject to certain exceptions, the Company has agreed to conduct, and to cause its relevant subsidiaries to conduct, the Business in the ordinary course of business in all material respects and to keep intact the business organizations and goodwill of the Business.
The representations and warranties made by each party were made solely for the benefit of the other party and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk between the parties to the Stock Purchase Agreement if those statements prove to be inaccurate; (ii) may have been qualified in the Stock Purchase Agreement by disclosures that were made to the other party in disclosure schedules to the Stock Purchase Agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of the Stock Purchase Agreement or such other date or dates as may be specified in the Stock Purchase Agreement.
The Stock Purchase Agreement does not contain indemnification provisions related to the representations and warranties in the agreement, and the representations and warranties of the parties will not survive post-closing.
Either party has the right to terminate the Stock Purchase Agreement under certain circumstances. Those circumstances include (i) mutual consent; (ii) as a result of a non-appealable governmental action or law under applicable antitrust laws that permanently enjoins or otherwise prohibits the transactions contemplated by the Stock Purchase Agreement; (iii) failure to consummate the Transaction by April 26, 2022 (the “Outside Date”); or (iv) as a result of certain material breaches by either party of its representations, warranties, agreements or covenants contained in the Stock Purchase Agreement if such breach has not been cured, if curable, within the earlier of thirty (30) days after notice of such breach and one (1) business day prior to the Outside Date.
The Purchaser has obtained equity commitments from certain funds affiliated with the Sponsor and a debt financing commitment (the “Debt Financing”) from a group of debt financing sources led by JPMorgan Chase Bank, N.A.
The Purchaser is required to pay the Company a termination fee of $112.775 million (the “Reverse Termination Fee”) if the Stock Purchase Agreement is terminated under certain circumstances specified in the Merger Agreement. Certain funds affiliated with the Sponsor have agreed to guarantee the obligations of the Purchaser under the Stock Purchase Agreement to pay the Reverse Termination Fee and related costs of collection, on the terms and subject to the conditions set forth in a limited guaranty in favor the Company.
The foregoing summary of the Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Purchase Agreement, which will be filed as an exhibit to TransUnion's Annual Report on Form 10-K for the year ended December 31, 2021.
Item 7.01 Regulation FD Disclosure.
On October 26, 2021, TransUnion issued a press release announcing their entry into the Stock Purchase Agreement. A copy of the press release is attached as Exhibit 99.1 hereto.
The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.1 shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by TransUnion under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless TransUnion expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
Press release of TransUnion, dated October 26, 2021 (furnished pursuant to Item 7.01). | ||||||||
| 104 | Cover page Interactive Data File (embedded within the inline XBRL file). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
| TRANSUNION | ||||||||
| Date: October 26, 2021 | By: | /s/ Todd M. Cello | ||||||
| Name: | Todd M. Cello | |||||||
| Title: | Executive Vice President, Chief Financial Officer | |||||||
Exhibit 99.1
TransUnion Announces Agreement to Sell TransUnion Healthcare to Clearlake Capital Group-Backed nThrive for $1.7 Billion
Chicago, IL, Oct. 26, 2021 – TransUnion (NYSE: TRU) has signed a definitive agreement to sell TransUnion Healthcare, Inc. (“TransUnion Healthcare”) to nThrive, Inc. (“nThrive”), a leading healthcare revenue cycle management (“RCM”) software-as-a-service (“SaaS”) platform backed by Clearlake Capital Group, L.P. (together with certain affiliates, “Clearlake”).
The transaction consideration is $1.735 billion in cash, and the transaction is expected to result in approximately $1.4 billion in after-tax proceeds at current tax rates. The parties are targeting to close the transaction in the fourth quarter of 2021, subject to the satisfaction of customary closing conditions and regulatory approvals. The proceeds will help TransUnion prepay debt and fund future M&A transactions that reinforce, extend and scale its core positions and which can be leveraged globally – such as the pending acquisitions of Neustar and Sontiq, both of which are expected to accelerate TransUnion’s long-term revenue growth.
“With the divestiture of TransUnion Healthcare, TransUnion will bring greater focus to our position as a global information and insights company providing credit, marketing and fraud mitigation solutions to help businesses and consumers transact with greater certainty,” said Chris Cartwright, President and CEO of TransUnion. “The transaction will also allow TransUnion Healthcare to benefit from ownership whose priorities and expertise are solely focused on healthcare revenue cycle management.”
Clearlake intends to combine TransUnion Healthcare with its portfolio company, nThrive, to strengthen its portfolio with powerful healthcare data and analytics capabilities that enable simple, efficient and accurate end-to-end RCM outcomes for healthcare providers and payers.
“We are confident that nThrive’s outstanding leadership and complementary portfolio make nThrive an ideal home for TransUnion Healthcare, and we look forward to a seamless transition,” added Cartwright.
About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company that makes trust possible in the modern economy. We do this by providing a comprehensive picture of each person so they can be reliably and safely represented in the marketplace. As a result, businesses and consumers can transact with confidence and achieve great things. We call this Information for Good.®
A leading presence in more than 30 countries across five continents, TransUnion provides solutions that help create economic opportunity, great experiences, and personal empowerment for hundreds of millions of people.
http://www.transunion.com/business
About TransUnion Healthcare
TransUnion Healthcare, a wholly owned subsidiary of TransUnion, makes trust possible by creating simplicity and transparency throughout the healthcare ecosystem to improve health and financial outcomes. TransUnion Healthcare is expected to generate approximately $190 million of revenue in 2021 at a mid-40 percent Adjusted EBITDA margin. TransUnion Healthcare helps over 1,850 hospitals and 650,000 physicians collectively recover more than $1.2 billion annually in revenue. TransUnion Healthcare’s Revenue Protection® solutions leverage comprehensive data, accurate insights and industry expertise to engage patients early, ensure earned revenue gets paid and optimize payment strategies.
https://www.transunionhealthcare.com
TransUnion Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of TransUnion’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those described in the forward-looking statements. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including our guidance and descriptions of our business plans and strategies. These statements often include words such as “anticipate,” “expect,” “guidance,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” “outlook,” “potential,” “continues,” “seeks,” “predicts,” or the negative of these words and other similar expressions.
Factors that could cause TransUnion’s actual results to differ materially from those described in the forward-looking statements include: the effects of the COVID-19 pandemic and the timing of the recovery from the COVID-19 pandemic; the possibility that the expected benefits of the proposed TransUnion Healthcare divestiture will not be realized, or will not be realized within the expected time period; failure to obtain governmental approvals of the proposed TransUnion Healthcare divestiture in the expected time period, or at all; the impact of the proposed TransUnion Healthcare divestiture on TransUnion’s businesses and the risk that consummating the proposed TransUnion Healthcare divestiture may be more difficult, time-consuming or costly than expected; the possibility that the proposed TransUnion Healthcare divestiture does not close, including failure to satisfy the closing conditions; failure to realize the synergies and other benefits expected from the proposed acquisitions of Neustar and Sontiq; delays in closing the proposed acquisitions; the possibility that the proposed acquisitions, including the integration of Neustar and Sontiq, may be more costly to complete than anticipated; risks related to the distraction of management from ongoing business operations and other opportunities due to the proposed acquisitions and the proposed TransUnion Healthcare divestiture; business disruption related to the proposed acquisitions and the proposed TransUnion Healthcare divestiture; the effects of pending and future legislation and regulatory actions and reforms; macroeconomic
and industry trends and adverse developments in the debt, consumer credit and financial services markets and other macroeconomic factors beyond TransUnion’s control; risks related to TransUnion’s indebtedness, including TransUnion’s ability to make timely payments of principal and interest and TransUnion’s ability to satisfy covenants in the agreements governing its indebtedness; and other one-time events and other factors that can be found in TransUnion’s Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, which are filed with the Securities and Exchange Commission and are available on TransUnion’s website (www.transunion.com/tru) and on the Securities and Exchange Commission’s website (www.sec.gov). Many of these factors are beyond our control. The forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to publicly release the result of any revisions to these forward-looking statements to reflect the impact of events or circumstances that may arise after the date of this press release.
Contact
Dave Blumberg
dblumberg@transunion.com
312-972-6646